This phase I trial is evaluating an oral drug (BGB-3111) in combination with another drug (obinutuzumab) for the treatment of B-Cell Non Hodgkin Lymphoma.
This trial is treating patients with B-Cell Non Hodgkin Lymphoma.
This is a systemic therapy.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
BeiGene Australia Pty Ltd
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with obinutuzumab in subjects with B-cell lymphoid malignancies.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More